Cann Group
Market Cap
AU$103.9m
Last Updated
2020/10/26 10:40 UTC
Data Sources
Company Financials +
Executive Summary
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. More Details
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Cann Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CAN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.3%
CAN
-8.8%
AU Pharmaceuticals
-1.4%
AU Market
1 Year Return
-64.6%
CAN
-30.5%
AU Pharmaceuticals
-7.1%
AU Market
Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -28.5% over the past year.
Return vs Market: CAN underperformed the Australian Market which returned -6.9% over the past year.
Shareholder returns
| CAN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -8.8% | -1.4% |
| 30 Day | -8.5% | -7.9% | 3.4% |
| 90 Day | -19.4% | -6.1% | 3.8% |
| 1 Year | -64.6%-64.6% | -30.4%-30.5% | -3.7%-7.1% |
| 3 Year | -80.2%-80.2% | -38.7%-39.6% | 16.9%2.1% |
| 5 Year | n/a | -31.7%-35.5% | 46.0%15.6% |
Price Volatility Vs. Market
How volatile is Cann Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Here's Why Cann Group (ASX:CAN) Can Afford Some Debt4 months ago | Simply Wall St
Cann Group Limited (ASX:CAN) Is Expected To Breakeven5 months ago | Simply Wall St
What Kind Of Investor Owns Most Of Cann Group Limited (ASX:CAN)?Valuation
Is Cann Group undervalued compared to its fair value and its price relative to the market?
0.88x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAN is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: CAN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAN is good value based on its PB Ratio (0.9x) compared to the AU Pharmaceuticals industry average (3.2x).
Next Steps
Future Growth
How is Cann Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
52.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAN's revenue (59.9% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: CAN's revenue (59.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAN is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Cann Group performed over the past 5 years?
-40.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAN is currently unprofitable.
Growing Profit Margin: CAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-27.73%), as it is currently unprofitable.
Next Steps
Financial Health
How is Cann Group's financial position?
Financial Position Analysis
Short Term Liabilities: CAN's short term assets (A$12.5M) exceed its short term liabilities (A$6.5M).
Long Term Liabilities: CAN's short term assets (A$12.5M) exceed its long term liabilities (A$8.8M).
Debt to Equity History and Analysis
Debt Level: CAN's debt to equity ratio (13.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CAN's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAN has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CAN is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
Next Steps
Dividend
What is Cann Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.5yrs
Average management tenure
CEO
Peter Crock
4.42yrs
Tenure
AU$492,065
Compensation
Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at Cann Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing an ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD349.95K) is about average for companies of similar size in the Australian market ($USD277.63K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.42yrs | AU$492.07k | 0.13% A$ 131.0k | |
| Chief Financial Officer | 0.50yr | AU$444.63k | no data | |
| Chief Operating Officer | 0.33yr | AU$298.44k | no data | |
| Chief Projects & Information Officer | 0.33yr | AU$3.76m | no data | |
| Chief Compliance Officer & Company Secretary | 0.83yr | AU$275.66k | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Head of Legal | no data | AU$204.01k | 0% A$ 0 |
0.5yrs
Average Tenure
Experienced Management: CAN's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Chairman | no data | AU$120.00k | 2.28% A$ 2.4m | |
| Independent Non-Executive Director | 5.58yrs | AU$60.00k | 0.86% A$ 897.5k | |
| Deputy Chairman | no data | AU$60.00k | 2.34% A$ 2.4m | |
| Director | 0.083yr | no data | 0.046% A$ 48.1k | |
| Independent Non-Executive Director | 4.5yrs | AU$60.00k | 0% A$ 0 |
4.5yrs
Average Tenure
Experienced Board: CAN's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CAN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 90.3%.
Top Shareholders
Company Information
Cann Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cann Group Limited
- Ticker: CAN
- Exchange: ASX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$103.915m
- Shares outstanding: 269.91m
- Website: https://www.canngrouplimited.com
Location
- Cann Group Limited
- Walter & Eliza Hall Inst. of Medical Res
- 4 Research Avenue
- Bundoora
- Victoria
- 3083
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CAN | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | May 2017 |
| CAN | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | May 2017 |
| CVJ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 2017 |
| CNGG.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | May 2017 |
Biography
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/26 10:40 |
| End of Day Share Price | 2020/10/26 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.